AAN 2017 POSTER DISCUSSION

 


The following is a selection of scientific posters presented at the American Academy of Neurology (AAN) annual meeting, Boston, MA, April 22-28, 2017.

Dr. Tjalf Ziemssen: 5 years safety of fingolimod in real world: First results from PANGAEA, a noninterventional study of RRMS patients treated with fingolimod, on safety and adherence after 5 years of fingolimod in daily clinical practice (P5.365)

Dr. Daniel Selchen: Therapeutic Inertia in Multiple Sclerosis: Applying Concepts of Behavioral Economics to Understand How Neurologists Make Decisions (P3.406)

Dr. Barry Singer: Durable Efficacy of Alemtuzumab in CARE-MS II Patients With RRMS With Disease Activity (Relapse) Between Courses 1 and 2 (P5.349)

Dr. Stuart Cook: Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis: An Integrated Analysis of Safety from the Multiple Sclerosis Clinical Development Program (Poster P5.394)


5 years safety of fingolimod in real world: First results from PANGAEA, a noninterventional study of RRMS patients treated with fingolimod, on safety and adherence after 5 years of fingolimod in daily clinical practice (P5.365)

Authors: T. Ziemssen, H. Albrecht, J. Haas, L. Klotz, M. Lang, C. Lassek, S. Schmidt, B. Tackenberg, C. Cornelissen


Back to top


Therapeutic Inertia in Multiple Sclerosis: Applying Concepts of Behavioral Economics to Understand How Neurologists Make Decisions (P3.406)

Authors: Gustavo Saposnik, Angel Perez Sempere, Daniel Prefasi, Daniel Selchen, Christian C Ruff, Jorge Maurino and Philippe N Tobler

Discussant: Dr. Daniel Selchen


Back to top


Durable Efficacy of Alemtuzumab in CARE-MS II Patients With RRMS With Disease Activity (Relapse) Between Courses 1 and 2 (P5.349)

Authors: Barry Singer, Heinz Wiendl, Simon Broadley, Mark S Freedman, Guillermo Izquierdo, Jan Lycke, Carlo Pozzilli, Brian Steingo, David H Margolin,Sourav Santra, Karthinathan Thangavelu, Aaron Boster; on behalf of the CARE-MS II and CAMMS03409 Investigators

Discussant: Dr. Barry Singer


Back to top


Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis: An Integrated Analysis of Safety from the Multiple Sclerosis Clinical Development Program (P5.394) Authors: S. Cook, T. Leist, G. Comi, X. Montalban, E. Sylvester, C. Hicking, F. Dangond

Discussant: Dr. Stuart Cook


Back to top

Recommend to a Colleague

Related Posts

Go back to home page